- Home
- UG vs ESLA Comparison
UG vs ESLA Comparison
Compare UG & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UG | ESLA |
|---|---|---|
| Founded | 1942 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.5M | 32.0M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | UG | ESLA |
|---|---|---|
| Price | $7.17 | $0.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 7.1K | ★ 37.9K |
| Earning Date | 05-11-2026 | 05-26-2026 |
| Dividend Yield | ★ 7.10% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $10,545,468.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $36.05 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.58 | $0.51 |
| 52 Week High | $8.45 | $3.15 |
Technical Indicators
Market Signals| Indicator | UG | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 49.39 | 27.46 |
| Support Level | $6.90 | N/A |
| Resistance Level | $7.48 | $0.85 |
| Average True Range (ATR) | 0.19 | 0.08 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 33.01 | 6.85 |
Price Performance
Historical ComparisonAbout UG United-Guardian Inc.
United-Guardian Inc manufactures, markets and develops specialty cosmetic, personal care and sexual wellness ingredients, and a line of healthcare products including pharmaceuticals and medical lubricants. Its pharmaceutical products are distributed through national drug wholesalers to pharmacies, physicians, and hospitals. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. The company's majority of revenue is derived from the sales of Pharmaceuticals in the United States.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.